A promising drug target, SETDB1, is a dual methyl-lysine (Kme) reader and methyltransferase implicated in cancer and neurodegenerative disease progression. To help understand the role of the triple Tudor domain (3TD) of SETDB1, its Kme reader, we first identify a low micromolar potency small molecule ligand, UNC6535, which occupies simultaneously both the TD2 and TD3 reader binding sites. Further optimization leads to the discovery of UNC10013, a covalent 3TD ligand targeting Cys385 of SETDB1. UNC10013 is potent with a k/K of 1.0 × 10 Ms and demonstrates proteome-wide selectivity. In cells, negative allosteric modulation of SETDB1-mediated Akt methylation occurs after treatment with UNC10013. Therefore, UNC10013 is a potent, selective, and cell-active covalent ligand for the 3TD of SETDB1, demonstrating negative allosteric modulator properties and making it a promising tool to study the biological role of SETDB1 in disease progression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850789 | PMC |
| http://dx.doi.org/10.1038/s41467-025-57005-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coadministration of scopolamine and mGlu2 receptor negative allosteric modulator VU6001966 as a potential therapeutic approach for depression: Rat frontal cortex neurochemistry and behavior.
Pharmacol Biochem Behav
March 2025
Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343, Kraków, Poland. Electronic address:
Clinical studies provide evidence that scopolamine, a nonselective antagonist of muscarinic cholinergic receptors, exerts rapid and prolonged antidepressant effects. However, its use as a psychiatric drug has been limited due to its significant adverse effects. A therapeutic option that could help reduce the adverse effects of scopolamine is its coadministration at lower doses with other substances with similar antidepressant properties.
View Article and Find Full Text PDFDeciphering the allosteric dynamics of GPR120-fatty acid interactions within a bilayer nanogold electrochemical receptor biosensor: the impact of replacing tryptophan 198 with proline.
Biomed Microdevices
March 2025
Tianjin Key Laboratory of Food Biotechnology, Institute of Collaborative Innovation in Great Health, College of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin, 300134, China.
GPR120 is a free fatty acid receptor capable of signalling excess fatty acids. GPR120 can be activated by various types of free fatty acids, causing intracellular signal transduction and exerting energy regulation, immune homeostasis, and neuronal functions. It has been suggested that Trp198 may be an important residue in the recognition and activation of GPR120 by fatty acid ligands, but direct experimental evidence is lacking.
View Article and Find Full Text PDFMolecular basis of β-arrestin coupling to the metabotropic glutamate receptor mGlu3.
Nat Chem Biol
March 2025
State Key Laboratory of Medicinal Chemical Biology and Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin, China.
β-Arrestins (βarrs) mediate the desensitization and internalization of activated G-protein-coupled receptors (GPCRs). The molecular mechanism by which dimeric family C GPCR members recruit arrestins remains elusive. Here we report two structures of metabotropic glutamate receptor subtype 3 (mGlu3) coupled to βarr1, with stoichiometries of 2:1 and 2:2.
View Article and Find Full Text PDFDesign, synthesis and pharmacological evaluation of 1,2,3,4-tetrahydrobenzofuro[2,3-]pyridine derivatives as p21-activated kinase 4 inhibitors for treatment of pancreatic cancer.
Acta Pharm Sin B
January 2025
Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
The p21-activated kinase 4 (PAK4), a key regulator of malignancy, is negatively correlated with immune infiltration and has become an emergent drug target of cancer therapy. Given the lack of high efficacy PAK4 inhibitors, we herein reported the identification of a novel inhibitor bearing a tetrahydrobenzofuro[2,3-]pyridine tricyclic core and possessing high potency against MIA PaCa-2 and Pan02 cell lines with IC values of 0.38 and 0.
View Article and Find Full Text PDFUnlabelled: Triple-negative breast cancer (TNBC) remains a leading cause of cancer associated deaths in women owing to its highly metastatic potential and limited treatment options. Recent studies have shown that expression of proteins associated with epigenetic regulation of gene expression are associated with metastatic relapse, however targeting epigenetic regulatory proteins has not resulted in effective therapies for TNBC in the clinic. The ABL tyrosine kinases promote metastasis of breast cancer cells in mouse models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!